These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1359055)

  • 1. Dose-dependent inhibition in plasma protein binding of valproic acid during continued treatment in guinea-pigs.
    Yu HY; Shen YZ
    J Pharm Pharmacol; 1992 May; 44(5):408-12. PubMed ID: 1359055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-dependent distribution volumes of total and unbound valproate in guinea-pigs: consequence of non-linear plasma protein binding.
    Yu HY; Shen YZ
    Biopharm Drug Dispos; 1996 Apr; 17(3):237-47. PubMed ID: 8983398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonlinear elimination and hepatic concentration of conjugation-metabolite of valproate in guinea-pigs.
    Yu HY; Wu MS; Shen YZ
    Biopharm Drug Dispos; 1993 May; 14(4):297-312. PubMed ID: 8499581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug interaction. Effects of salicylate on pharmacokinetics of valproic acid in rats.
    Yu HY; Shen YZ; Sugiyama Y; Hanano M
    Drug Metab Dispos; 1990; 18(1):121-6. PubMed ID: 1970771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonlinear binding of valproic acid (VPA) and E-delta 2-valproic acid to rat plasma proteins.
    Semmes RL; Shen DD
    Pharm Res; 1990 May; 7(5):461-7. PubMed ID: 2114617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of valproate on the pharmacokinetics of free and total plasma bilirubin in experimental hyperbilirubinemia in guinea pigs.
    Yu HY; Shen YZ
    J Pharm Sci; 1998 Jan; 87(1):21-4. PubMed ID: 9452963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of valproic acid in guinea-pigs with biliary abnormality.
    Yu HY; Shen YZ
    J Pharm Pharmacol; 1991 Jul; 43(7):470-4. PubMed ID: 1682459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid.
    Barré J; Chamouard JM; Houin G; Tillement JP
    Clin Chem; 1985 Jan; 31(1):60-4. PubMed ID: 3917383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-dependent pharmacokinetics of valproate in guinea pigs of different ages.
    Yu HY; Shen YZ; Sugiyama Y; Hanano M
    Epilepsia; 1987; 28(6):680-7. PubMed ID: 3121286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in pharmacokinetics of valproic acid in guinea pigs from birth to maturity.
    Yu HY; Sugiyama Y; Hanano M
    Epilepsia; 1985; 26(3):243-51. PubMed ID: 3924587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of free fatty acids on valproic acid plasma protein binding during fasting in normal humans.
    Bowdle TA; Patel IH; Levy RH; Wilensky AJ
    Eur J Clin Pharmacol; 1982 Oct; 23(4):343-7. PubMed ID: 6816619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between valproic acid and carbamazepine: an in vitro study of protein binding.
    Mattson GF; Mattson RH; Cramer JA
    Ther Drug Monit; 1982; 4(2):181-4. PubMed ID: 6808714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of serum protein binding in epileptic children during sodium valproate maintenance therapy.
    Yu HY
    Ther Drug Monit; 1984; 6(4):414-23. PubMed ID: 6440321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of tissue distribution of valproate in guinea-pigs: evidence for its capacity-limited tissue distribution.
    Yu HY; Shen YZ
    Pharm Res; 1995 Mar; 12(3):421-5. PubMed ID: 7617531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valproic acid: in vitro plasma protein binding and interaction with phenytoin.
    Cramer JA; Mattson RH
    Ther Drug Monit; 1979; 1(1):105-16. PubMed ID: 121944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can the serum protein binding of valproic acid limit the hepatic elimination?
    Kodama Y; Kuranari M; Teraoka I; Fujii I; Takeyama M
    Int J Clin Pharmacol Ther Toxicol; 1993 Nov; 31(11):529-32. PubMed ID: 8294164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No effect of gender or age on binding characteristics of valproic acid to serum proteins in pediatric patients with epilepsy.
    Kodama Y; Kodama H; Kuranari M; Tsutsumi K; Ono S; Fujimura A
    J Clin Pharmacol; 1999 Oct; 39(10):1070-6. PubMed ID: 10516942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma protein binding kinetics of valproic acid over a broad dosage range: therapeutic implications.
    Gómez Bellver MJ; García Sánchez MJ; Alonso González AC; Santos Buelga D; Domínguez-Gil A
    J Clin Pharm Ther; 1993 Jun; 18(3):191-7. PubMed ID: 8345004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma protein binding interaction between valproic and salicylic acids in rhesus monkeys.
    Viswanathan CT; Levy RH
    J Pharm Sci; 1981 Nov; 70(11):1279-81. PubMed ID: 6795339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein binding and hepatobiliary distribution of valproic acid and valproate glucuronide in rats.
    Brouwer KL; Hall ES; Pollack GM
    Biochem Pharmacol; 1993 Feb; 45(3):735-42. PubMed ID: 8442771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.